Elanco Animal Health INC 8-K filings

Elanco Animal Health reported a robust second quarter of 2026 with 10% revenue growth, driven by strong performance in Pet Health and Farm Animal segments, leading to an increased full-year financial outlook.

Elanco Animal Health Incorporated reports the successful election of directors and ratification of auditors at its 2026 annual meeting.

Elanco Animal Health reported strong first quarter 2026 results, with revenue up 15% year-over-year, and raised its full-year financial guidance.

Elanco Animal Health reported strong fourth quarter and full year 2025 results, exceeding innovation revenue targets and providing optimistic 2026 guidance in line with its Investor Day outlook.

Elanco Animal Health presented its strategy for consistent growth, innovation, and cash generation at the 44th Annual J.P. Morgan Healthcare Conference, reaffirming its 2025 outlook and projecting significant future expansion.

Elanco Animal Health Inc. announced a restructuring plan, a new three-year financial outlook, and significant innovation pipeline updates at its Investor Day.

Elanco Animal Health reported robust third-quarter 2025 results, exceeding expectations and prompting an upward revision of its full-year financial guidance and innovation targets.

Elanco Animal Health Incorporated has amended its credit agreement to refinance existing term loans, securing new U.S. dollar and Euro-denominated facilities with extended maturity dates.

Elanco Animal Health reported strong second quarter 2025 results, exceeding expectations and leading to an increased full-year revenue and earnings outlook, driven by new product innovation and accelerated debt reduction.

Elanco Animal Health Incorporated has announced the extension of its significant accounts receivable securitization facility by approximately two years, ensuring continued access to vital liquidity.

Elanco Animal Health Incorporated announced the appointment of Robert VanHimbergen as its new Executive Vice President and Chief Financial Officer, effective July 7, 2025, succeeding Todd Young who will transition to an advisory role.

Elanco Animal Health Incorporated held its annual shareholder meeting on May 16, 2025, where directors were elected, the appointment of Ernst & Young LLP was ratified, and executive compensation was approved in a non-binding vote.

Elanco Animal Health reports a mixed Q1 2025 with a slight revenue dip but raises full-year revenue guidance driven by foreign exchange tailwinds and strong performance.

Elanco Animal Health announces changes to its Board of Directors and a research agreement with WEDterinary LLC to explore gene therapy for chronic kidney disease and life extension in pets.

Elanco Animal Health reports a slight revenue decrease in Q4 2024 but exceeds its innovation revenue target for the full year and raises the 2025 target.

Elanco Animal Health presented at the J.P. Morgan Healthcare Conference, highlighting its growth strategy, pipeline of potential blockbuster products, and financial outlook for 2025.

Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately, bringing extensive experience in biopharmaceutical development and manufacturing.

Elanco Animal Health reported a mixed third quarter with revenue slightly down but organic growth up 1%, and tightened its full-year 2024 financial guidance.

Elanco Animal Health reports positive serologic response to core booster vaccinations in dogs treated with Zenrelia (ilunocitinib) and announces approval for the drug in Canada.

Elanco Animal Health has entered into an agreement for a new $350 million term loan facility to repay existing debt and for general corporate purposes.

Elanco Animal Health reported a strong second quarter with revenue growth and has raised its full-year revenue guidance while maintaining adjusted EBITDA guidance, excluding the impact of the aqua business divestiture.

Elanco Animal Health has completed the sale of its aqua business to Merck Animal Health for approximately $1.3 billion, focusing on pet health and livestock sustainability.

Elanco Animal Health has amended its credit agreement, extending the maturity date of its revolving credit facility to July 3, 2029, and making other modifications to covenants and terms.

Elanco Animal Health rebalanced its board of directors, declassified the board structure, and adopted a majority vote standard for uncontested director elections at its annual shareholder meeting.

Elanco Animal Health reported strong first-quarter results, exceeding expectations for revenue, adjusted EBITDA, and adjusted EPS, and updated its full-year guidance to reflect improved operational performance.

Elanco Animal Health has appointed Kathy V. Turner and Craig S. Wallace to its Board of Directors and reached a cooperation agreement with Ancora Catalyst Institutional, LP.

Elanco Animal Health reported its fourth quarter and full year 2023 results, announced a strategic restructuring, and provided initial guidance for 2024, including the sale of its aqua business.

Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash, allowing Elanco to focus on pet health and livestock sustainability.